Melatonin treatment improves primary progressive multiple sclerosis: A case report

Antonio Lõpez-González, Nuria Álvarez-Sánchez, Patricia J. Lardone, Ivan Cruz-Chamorro, Alicia Martínez-Lõpez, Juan M. Guerrero, Russel J. Reiter, Antonio Carrillo-Vico

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


We describe the case of a female patient who, at the age of 28, was diagnosed with symptoms of primary progressive multiple sclerosis (PPMS). Glucocorticoid treatment was immediately initiated. The disease and the demyelinating lesions progressed during the following 9 years reaching Expanded Disability Status Scale (EDSS) 8.0 (patient essentially restricted to bed, a chair or perambulated in a wheelchair). At this point, the patient began taking melatonin at doses ranging from 50 to 300 mg per day. Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6.0 (the person needs intermittent or unilateral constant assistance such as cane, crutch, or brace to walk 100 meters with or without resting). This long-lasting improvement is likely due to melatonin usage since it is related in time and because of its exceptionally long duration.

Original languageEnglish (US)
Pages (from-to)173-177
Number of pages5
JournalJournal of pineal research
Issue number2
StatePublished - Mar 2015


  • melatonin
  • multiple sclerosis
  • primary progressive multiple sclerosis

ASJC Scopus subject areas

  • Endocrinology


Dive into the research topics of 'Melatonin treatment improves primary progressive multiple sclerosis: A case report'. Together they form a unique fingerprint.

Cite this